Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 21, Iss. 2, 2018-02 ,pp. : 402-414

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 6, 2015-06 ,pp. : 1424-1437

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24‐Week Patient‐Reported Outcome Results of a Phase III, Multicenter Study

By  

ARTHRITIS CARE AND RESEARCH, Vol. 66, Iss. 7, 2014-07 ,pp. : 1085-1092

John Wiley & Sons Inc

Access to resources Recommend Favorite

Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 11, 2014-11 ,pp. : 2924-2937

John Wiley & Sons Inc

Access to resources Recommend Favorite

Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1627-1636

John Wiley & Sons Inc

Access to resources Recommend Favorite